Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Initiates Coverage On Terns Pharma with Neutral Rating, Announces Price Target of $6

HC Wainwright & Co. analyst Ed Arce initiates coverage on Terns Pharma (NASDAQ:TERN) with a Neutral rating and announces Price Target of $6.
byBenzinga Newsdesk
September 12, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Ed Arce initiates coverage on Terns Pharma (NASDAQ:TERN) with a Neutral rating and announces Price Target of $6.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cansortium Cuts Loss YoY, Reports 14% Increase In Q1 Revenue Driven By Florida Cannabis Sales Ahead Of Merger With RIV Capital

By Jelena Martinovic
May 31, 11:34 AM
Cansortium Inc. (CSE: TIUM.U) (OTCQB: CNTMF) a vertically-integrated, multi-state cannabis company operating under the FLUENT brand, announced on Thursday financial and operating results for the first quarter ended March 31, 2024."We delivered another quarter of year-over-year revenue growth and positive cash flow generation during the first quarter as we continued to execute on our growth objectives," CEO Robert Beasley said. "We are making the critical investments needed to lay the foundation for growth and support our future plans and remain excited about the opportunities ahead."

CNPOF